Facilities & Services
 

3D-Hub-S Facility

Cedric GAGGIOLI, Research Director, DR2 Inserm
 

 

In drug discovery programs, multicellular spheroids and tumoroids have emerged as powerful tools to bridge the gap between in vitro cell culture models and in vivo tissues. 3D tumor cultures are a promising tool for in vitro rebuilding the in vivo behaviour of cancer cells for the development and validation of anti-tumor therapies. Yet, in vitro models capable to realistically mimic the complex ecosystem of solid tumors is an unmet need. In solid cancer mutual interactions between the epithelial transformed cancer cells and their surrounding partners, (including stromal non-transformed cells; carcinoma-associated fibroblasts, endothelial cells, adipocytes, pericytes, innate and adaptive immune cells) embedded within a complex extracellular matrix (ECM), favour tumor development, metastatic spreading and resistance to chemotherapeutic treatments. Therefore, the development of 3D multicellular spheroids and tumoroids embedded in a collagen rich matrix in vitro would significantly improve the early phase of drug discovery in preclinical cancer research.

3d-Hub-S, a platform supported by the Cancéropôle Provence Alpes Côte d’Azur, proposes the development of the 3D-Hub platform that will generate 3D biological structures to perform drugs screening for novel anti-cancer therapies and to develop . The 3D-Hub platform will be set up for academic and clinical laboratories between Marseille (3D-Hub-O) and Nice (3D-Hub-S).

Facilities & Services